Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3R1 | P27986 | 2/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PDE8B | O95263 | 1/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1163076 | 0.81 | CNR1 (0.49) | CNR1CNR2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL4317819 | 0.81 | PIK3R1 (0.53) | PIK3R1PIK3CACNR1CNR2ALDH1A1 | |
| SCHEMBL1692623 | 0.80 | ESRRA (0.39) | PIK3R1PIK3CA | |
| SCHEMBL9909981 | 0.78 | CNR2 (0.46) | PIK3R1PIK3CACNR1CNR2CYP1A2 | |
| SCHEMBL24423075 | 0.77 | CNR1 (0.46) | CNR1CNR2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL24424093 | 0.77 | PTGER4 (0.49) | CNR1CNR2PTGER4MAPT | |
| SCHEMBL1163283 | 0.76 | CNR2 (0.56) | PIK3R1PIK3CACNR1CNR2MAPT | |
| SCHEMBL19597373 | 0.75 | ADORA2A (0.59) | CACNA1H | |
| SCHEMBL24147762 | 0.75 | CNR1 (0.46) | PIK3R1PIK3CACNR1CNR2ALDH1A1 | |
| SCHEMBL16533912 | 0.74 | KMO (0.52) | CNR1CNR2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871765-B1 | 3-(INDAZOL-5-YL)-(1,2,4)TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORP (US) | 2009-12-09 | — | — | EP | disclosed |
| US-7528132-B2 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; indazolyl [1,2,4]triazine compounds | SCHERING CORPORATION (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080004257-A1 | Kinase inhibitors | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| EP-1871765-A2 | 3-(INDAZOL-5-YL)-(1,2,4)TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006081230-A2 | 3-(INDAZOL-5-YL)-(1,2, 4) TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004257-A1 | Kinase inhibitors | MAP3K1, MAP3K13, MAP3K6 | PIK3R1 537/4885PIK3CA 157/4885PDE5A 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.